Posts belonging to Category Uncategorized

HIGHER EDUCATION SCHOLARSHIPS 2014-2015

2014-2015 Scholarship Recipients!The RASCALS Foundation is proud to announce their selection of recipients for the Higher Education Scholarship program for the 2014-2015 academic year.
But first, we would like to thank all of the individ…uals who participated in the program. We would like to thank our supporters for their partnership over the years. We would like [...]

ALS Awareness Facts: Day 5

ALS is almost always fatal. Motor neurons also control the respiratory system. So when they begin to deteriorate and eventually die off, this brings on respiratory complications which impair a person’s ability to breathe. Many ALS patients eventually die from pneumonia.

ALS Awareness Facts: Day 1

The RASCALS Foundation is doing everything it can year-round to spread the message about Lou Gehrig’s disease. In reality, this is everybody’s disease—and there is so much more to do. In addition to raising awareness, we need to raise much-needed financial resources for the ALS community.

Q Therapeutics Issues Formal Update

Q Therapeutics is moving forward to clinical studies using their proprietary, patented Q-Cells® as a potential therapy for Amyotrophic Lateral Sclerosis (ALS, or Lou Gehrig’s disease).

The RASCALS Foundation Announces Higher Education Scholarships for 2014

The RASCALS Foundation is pleased to announce that it is once again offering  the 2014 Higher Education Scholarship Program to assist families affected by ALS. We would like to acknowledge and thank our newest partner Helping Hands for ALS, a student group associated with John Burroughs High School for their generous participation in making these [...]

Acceleration of Clinical Program in ALS Confirms Proof of Efficacy Data Obtained in Animals

AB Science SA, a pharmaceutical company specialized in research, development and marketing of protein kinase inhibitors (PKIs), announces, following the press release from November 4, that the acceleration of the clinical development program in ALS is in line with proof of efficacy experiments conducted in two different models that generated positive results of increased survival.

Last Day to Pre-Register for the RASCALS Foundation 5K Walk/Run in Tower Grove Park, November 2nd

Please join the Robert A. Stehlin Campaign for ALS (RASCALS) to “Fight ALS One Step At A Time”
on Saturday, Nov. 2nd, Tower Grove Park.

Lou Gehrig’s Disease Twice as Likely to Strike Military Veterans

“We’re trying to prime the pump and fund (researchers) before they go into clinical trials,” said Melissa Forsythe, director of the Pentagon’s ALS Research Program. “Our goal every year is to make the very best investment we can.”

New ALS Drug Headed for Phase IIa Trial

Researchers at Houston Methodist Neurological Institute and elsewhere will soon begin phase IIa clinical trials of TDI-132, a drug that in animal models has shown promise in reducing the inflammation associated with Amyotrophic Lateral Sclerosis, also known as ALS or Lou Gehrig’s Disease.

Michael R. Brand Announced as New Secretary of RASCALS Board of Directors

The Robert A. Stehlin Campaign for ALS (R.A.S.C.A.L.S.) is pleased to announce the election of Michael R. Brand to the foundation’s Board of Directors as Secretary, his duties include ensuring that board business is conducted in compliance with its bylaws, providing fiscal oversight, and maintaining a continuity of policies and practices in keeping with 501(c)(3) legal requirements.